Kyowa Kirin
As of the edition of 20 October 2026, Kyowa Kirin runs 49 drugs, 17 of them marketed; it is on route A at 12 targets and on route B at 10 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 8 company names in this family.
- Orchard Therapeutics: acquired in 2024; successor KYOWA KIRIN CO., LTD.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 17 |
| Active | 8 |
| Went quiet | 10 |
| Stopped | 13 |
| Status not established | 1 |
| Total | 49 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Fluorouracil | none listed | 2 |
| Filgrastim | Ended 2022 (orphan exclusivity) | 3 |
| Pegfilgrastim | Ended 2022 (orphan exclusivity) | 3 |
| Mitomycin | none listed | 0 |
| Darbepoetin alfa | Ended 2013 (computed from the first US licence) | 1 |
| Medroxyprogesterone acetate | none listed | 1 |
| Benralizumab | Ends 2031 (orphan exclusivity) | 0 |
| Romiplostim | Ends 2028 (orphan exclusivity) | 2 |
| Brodalumab | Ends 2029 (computed from the first US licence) | 3 |
| Tivozanib | Ends 2028 (patent) | 5 |
| Mogamulizumab | Ends 2030 (computed from the first US licence) | 1 |
| Tenapanor | Ends 2033 (patent) | 2 |
| Toremifene | none listed | 0 |
| Burosumab | Ends 2030 (computed from the first US licence) | 1 |
| Istradefylline | none listed | 1 |
| Evocalcet | none listed | 1 |
| Atidarsagene autotemcel | Ends 2036 (reference-product exclusivity) | 0 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 12 targets, route B at 10 targets.
All 22 rows on route A or B
In the product22 company-target rows on route A or B; 19 are not shown here, and no score is.
See all 22 targets where Kyowa Kirin needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Cancer: 40 trials led
- Nervous system: 28 trials led
- Hormones: 19 trials led